A common key regulator of oncogenic signaling pathways in multiple tumor types is the unique isomerase Pin1. However, available Pin1 inhibitors lack the required specificity and potency for inhibiting Pin1 function in vivo. By using mechanism-based screening, here we find that all-trans retinoic acid (ATRA)-a therapy for acute promyelocytic leukemia (APL) that is considered the first example of targeted therapy in cancer, but whose drug target remains elusive-inhibits and degrades active Pin1 selectively in cancer cells by directly binding to the substrate phosphate-and proline-binding pockets in the Pin1 active site. ATRA-induced Pin1 ablation degrades the protein encoded by the fusion oncogene PML-RARA and treats APL in APL cell and animal models as well as in human patients. ATRA-induced Pin1 ablation also potently inhibits triple-negative breast cancer cell growth in human cells and in animal models by acting on many Pin1 substrate oncogenes and tumor suppressors. Thus, ATRA simultaneously blocks multiple Pin1-regulated cancer-driving pathways, an attractive property for treating aggressive and drug-resistant tumors. degrades active Pin1, thereby exerting potent anticancer activity against APL and triple-negative breast cancer (TNBC) by simultaneously blocking multiple Pin1-regulated cancer-driving pathways.
Targeted therapy has changed cancer treatment, but blocking a single pathway is often ineffective against solid tumors, especially aggressive or drug-resistant ones, because of activation of redundant and/or alternative oncogenic pathways 1 . Thus, knowing how to block the multiple cancer-driving pathways simultaneously remains a major challenge. A common and central signaling mechanism in oncogenic pathways is proline-directed phosphorylation (pSer/Thr-Pro) 2 . Numerous oncogenes and tumor suppressors are either directly regulated by ( Supplementary Fig. 1 ) and/or trigger signal pathways involving such phosphorylation 2, 3 . Notably, the same kinases often phosphorylate both oncogenes and tumor suppressors to control their function. The prolyl isomerase (PPIase) Pin1 has a critical role in coordinating these multiple phosphorylation events to oncogenesis 2, 3 .
Proline uniquely adopts cis and trans conformations, and its isomerization is catalyzed by PPIases 4 , including the unique PPIase Pin1 (refs. 2, 5, 6) . Using its WW domain, Pin1 binds to specific pSer/Thr-Pro motif(s), in which its PPIase domain catalyzes cis-trans isomerization of certain pSer/Thr-Pro motifs 5 , which can be detected by cis-and trans-specific antibodies 6 . Pin1 is commonly overexpressed and/or activated in human cancers, which correlates with poor outcomes 3, 7 . In contrast, Pin1 polymorphisms that lower Pin1 expression are associated with reduced cancer risk compared to the normal population 8 .
Moreover, Pin1 deficiency in mice prevents tumorigenesis, even that induced by activated oncogenes such as Erbb2 (encoding HER2) or Kras (encoding Ras) 9 , whereas Pin1 overexpression disrupts cell cycle coordination and leads to centrosome amplification, chromosome instability, and cancer development in cell and animal models of breast cancer 10 . Pin1 activates at least 32 oncogenes and growthpromoting proteins, and inactivates at least 19 tumor suppressors and growth-inhibiting proteins 2, 3, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] ( Supplementary Fig. 1 ). Thus, Pin1 can amplify oncogenic pathways by simultaneously activating oncogenes and inactivating tumor suppressors. Pin1 also has a fundamental role in driving expansion and tumorigenesis of cancer stem cells [21] [22] [23] , a major source of cancer resistance 1 . These studies suggest that Pin1 inhibitors could have the unique and desirable ability to block multiple cancer-driving pathways and inhibit cancer stem cells at the same time 2, 3, 24 , especially given that Pin1-knockout (KO) mice develop normally without obvious defects for an extended period of time 25, 26 .
However, the available Pin1 inhibitors either lack the required specificity and/or potency or cannot efficiently enter cells to inhibit Pin1 function in vivo 3, 27 . Here we developed mechanism-based high-throughput screening for compounds targeting active Pin1. We found that ATRA (tretinoin) directly and selectively binds, inhibits and ultimately 13cRA and its isomer, ATRA (Fig. 1b,c) , bound to Pin1 in the FP assay, with ATRA being more potent than 13cRA after a short period of incubation (K i = 1.16 and 0.58 µM, respectively, calculated using an equation as previously described 30 ) (Supplementary Fig. 3a ), but this difference disappeared after a longer incubation ( Supplementary Fig. 3b,c) . These results suggest that Pin1 may mainly bind to the trans form (ATRA) but that it can bind to the cis form (13cRA) after it is converted to the trans form, which does occur over time both in vitro and in vivo 31 . The ATRA-Pin1 interaction was confirmed using a different fluorescence-labeled pTide probe (Supplementary Fig. 2h ). As [ 3 H]ATRA has been used as a photoaffinity-labeling reagent to covalently and specifically tag ATRA-binding proteins 32 , we performed photoaffinity labeling of Pin1 with [ 3 H]ATRA, and subsequently detected the binding using SDS-containing gels. [ 3 H]ATRA directly bound to Pin1 (K d = 0.80 µM) (Fig. 1d,e and Supplementary Fig. 3a) . Moreover, ATRA and 13cRA fully inhibited the PPIase activity of Pin1, with K i values of 0.82 and 2.37 µM, respectively, which were similar to those from the FP assay ( Fig. 1f and Supplementary Fig. 3a,d,e) , but neither compound inhibited cyclophilin and FKBP12, other major PPIases ( Supplementary Fig. 3f,g ). Thus, ATRA is a submicromolar Pin1 inhibitor.
ATRA binds to the Pin1 active site
To determine whether the carboxylic acid in ATRA serves as an alternative to the phosphate group for binding to Pin1, several structurally similar retinoids with substituted carboxylic or aromatic groups and 33 and bexarotene 34 , were tested for Pin1 binding. ATRA was the most potent against Pin1 out of those tested ( Fig. 1g and Supplementary Fig. 4a) . Notably, carboxylic acid group (-COOH)-substituted retinoids, including retinol (-OH), retinyl acetate (-OCOCH 3 ) and retinal (-CHO) were totally inactive ( Fig. 1g and Supplementary Fig. 4a ). In line with this, fenretinide and bexarotene showed only marginal Pin1 binding ( Fig. 1g and Supplementary Fig. 4a ), which might be due to the lack of a carboxyl group and/or modifications to target retinoic acid receptors (RARs), retinoid X receptors (RXRs), or others [33] [34] [35] .
To understand how ATRA inhibits Pin1 catalytic activity, we determined the co-crystal structure of ATRA and the Pin1 PPIase domain ( Supplementary Fig. 4b and Supplementary Table 1) . After ATRA soaking, strong electron density was observed at the Pin1 active site (Fig. 1h) . The most-well-defined region of ATRA was its carboxyl group, which formed salt bridges with Pin1's critical catalytic residues K63 and R69 (Fig. 1i) , both of which are essential for binding the phosphate group in the Pin1 substrate 29 . At the high resolution of 1.3 Å, two alternative conformations of R69 were visible, both of which were within the distance range needed for salt bridge formation with the carboxyl group of ATRA. The trimethylcyclohexene ring of ATRA was sandwiched within Pin1's hydrophobic Pro-binding pocket, which is formed by L122, M130, Q131 and F134 (ref. 29) (Fig. 1i) . Notably, the binding modes of ATRA and pTide overlapped Fig. 1i and Supplementary Fig. 2b) . Thus, by mimicking the pSer/Thr-Pro motif in a substrate, the carboxylic and aromatic moieties of ATRA bind to the substrate phosphate-and proline-binding pockets of the Pin1 active site, respectively. These structural requirements were also consistent with our findings that the carboxyl group of ATRA was required for binding to Pin1, and that fenretinide and bexarotene were less potent than ATRA in binding Pin1 (Fig. 1g) .
ATRA induces Pin1 degradation and inhibits its function
To determine whether ATRA inhibits Pin1 activity in cells, we first compared its effects on the proliferation of Pin1-KO (Pin1 −/− ) and wildtype (WT, Pin1 +/+ ) mouse embryonic fibroblasts (MEFs). Relatively high concentrations of ATRA were required to inhibit the growth of Pin1 WT MEFs, and Pin1-KO cells were more resistant than Pin1 WT MEFs to ATRA (Fig. 2a) . Susceptibility to ATRA was fully restored by re-expressing Pin1 but not its inactive W34/K63A mutant (Fig. 2a) . Notably, ATRA also dose-dependently downregulated levels of WT but not mutant Pin1 protein (Fig. 2b) . ATRA had no obvious effects on Pin1 mRNA levels (Fig. 2c) . ATRA reduced protein levels of both exogenous and endogenous Pin1, but not that of the W34/K63A mutant, which did not bind ATRA (Fig. 2b and Supplementary Fig. 2g ). ATRA-induced Pin1 degradation was suppressed by the proteasome inhibitor MG132 (Fig. 2d) . Both ATRA and 13cRA reduced Pin1 protein half-life (Fig. 2e) , but ATRA was more potent (Fig. 2b,e) . Next we examined the effects of ATRA on well-documented oncogenic phenotypes induced by Pin1 overexpression, such as centrosome amplification 10 , activation of the cyclin D1 promoter 11 and enhanced foci formation; all of these phenotypes are inhibited by DAPK1-mediated Pin1 phosphorylation at S71 (ref. 7) . ATRA dosedependently and fully inhibited the ability of Pin1 overexpression to induce centrosome amplification in NIH 3T3 MEFs (Fig. 2f,g ), as well as its ability to activate the cyclin D1 promoter and enhance foci formation in SKBR3 cells ( Fig. 2h-j) . Thus, ATRA induces Pin1 degradation and inhibits its oncogenic function.
Pin1 is a key target of ATRA in APL cells ATRA is approved to treat APL, in which it activates RARs to induce APL cell differentiation and also causes degradation of the fusion protein promyelocytic leukemia-retinoic acid receptor α (PML-RAR-α) to inhibit self-renewal of APL stem cells [36] [37] [38] . However, ATRA-induced RAR-α activation can be decoupled from its ability to degrade PML-RAR-α and treat APL 39, 40 . Notably, retinoid analogs that potently activate RARs and induce leukemia cell differentiation, but fail to induce PML-RAR-α degradation, also fail to inhibit self-renewal of leukemia stem cells and treat APL 40 . Moreover, ATRA's ability to activate RARs cannot readily explain its ability to destabilize other oncogenic molecules, including cyclin D1 (ref. 41) and NF-κB 42 , or its ability to stabilize tumor-suppressive molecules such as Smad 43 . Thus, the cellular target(s) of ATRA that mediate its anticancer effects remain elusive.
To examine the role of RARs in ATRA-directed degradation of PML-RAR-α, we used a pan-RAR agonist, AC-93253, and a pan-RAR inhibitor, Ro-415253, both of which are structurally distinct from ATRA ( Supplementary  Fig. 5a ) and exhibit the expected ability to activate or inhibit transcription of RAR downstream targets, respectively ( Supplementary  Fig. 5b ). Ro-415253 showed minimal Pin1 binding and AC-93253 showed no binding ( Supplementary Fig. 5c ). Ro-415253 neither prevented ATRA from inducing degradation of Pin1 or PML-RAR-α ( Supplementary Fig. 5d ) nor inhibited the growth of NB4 human APL cells 44 ( Supplementary Fig. 5e ), whereas AC-93253 did not mimic ATRA-induced Pin1 or PML-RAR-α degradation ( Supplementary Fig. 5f ). These RAR-independent ATRA effects were also confirmed using RAR-α, RAR-β, and RAR-γ triple-KO MEFs 40 , in which ATRA induced degradation of PML-RAR-α and Pin1 similarly to what was observed in WT controls ( Supplementary Fig. 5g,h ). ATRA-induced PML-RAR-α degradation is associated with phosphorylation of the Ser581-Pro motif of PML-RAR-α (ref. 39) , which corresponds to the Pin1 binding site pSer77-Pro in RAR-α (ref. 45) . Because Pin1 binds to and increases the protein stability of numerous oncogenes 2, 3 (Supplementary Fig. 1 ), we hypothesized that Pin1 might bind to the pS581-Pro motif in PML-RAR-α and stabilize it, thereby promoting APL cell growth. Indeed, Pin1 interacted with PML-RAR-α, and the S581A but not the S578A mutation abolished this interaction (Supplementary Fig. 6a ) and reduced PML-RAR-α stability 2,3 ( Supplementary Fig. 6b,c) . Moreover, Pin1 knockdown (KD) using a validated shRNA-containing lentivirus 7 reduced PML-RAR-α stability and inhibited APL cell growth compared to pLKO vector control; both effects were rescued by re-expression of shRNA-resistant Pin1, but not of its inactive mutant (Fig. 3a-e) . In contrast to PML-RAR-α, Pin1 interacted much less with promyelocytic leukemia zinc finger ortholog (PLZF)-RAR-α ( Supplementary  Fig. 7a) , and Pin1 KD only marginally reduced the protein stability of PLZF-RAR-α, as compared with PML-RAR-α ( Supplementary  Fig. 7b-e) . Although future experiments are needed to define the underlying mechanisms, these results are consistent with the fact that APL induced by PLZF-RAR-α is usually resistant to ATRA [36] [37] [38] .
To expand our investigation beyond PML-RAR-α, we compared genome-wide gene expression profiles of ATRA-or DMSO-treated NB4 cells and NB4 cells stably expressing either pLKO vector control or Pin1 shRNA using microarrays that covered coding and noncoding transcripts in the human whole genome. Clustering analysis revealed a similarity between ATRA-treated and Pin1 shRNA-expressing cells. 528 genes were differentially expressed both in Pin1-KD cells and ATRAtreated cells, as compared with their respective controls. 304 genes were upregulated, including many growth suppressors (for example, Table 2 ). Thus, both PML-RAR-α gene-specific and genome-wide analyses support the idea that ATRA inhibits Pin1 in APL cells. We corroborated these in vitro results in animal studies using sublethally irradiated immunodeficient NOD scid gamma (NSG) mice transplanted with NB4 cells stably expressing an inducible tetracycline-controlled (Tet-on) shPin1 (ref. 46) . When doxycyclinecontaining food was given 5 d after transplantation and throughout the remaining course of the experiment, Pin1 and PML-RAR-α expression decreased in the bone marrow (Fig. 3g) . In contrast to mice given control food, which exhibited splenomegaly, mice fed doxycycline displayed normal spleen size (Fig. 3h and Supplementary Fig. 8a ). Doxycycline-fed mice also contained fewer human CD45-expressing NB4 cells in the bone marrow (Supplementary Fig. 8b-d) . Diseasefree survival of doxycycline-fed mice was also substantially extended compared to that of mice fed control chow (Fig. 3i) . Notably, in one doxycycline-fed mouse that died early (i.e., before the other mice), Pin1 and PML-RAR-α were expressed in amounts close to those in mice not fed doxycycline (Fig. 3j) , thereby supporting the role of Pin1 and its effects on PML-RAR-α in survival of mice with APL. Thus, as is the case with ATRA, inducible Pin1 KD alone is sufficient to cause PML-RAR-α degradation and treat APL in animal models.
ATRA and Pin1 inhibition suppress APL growth
We compared the effects of ATRA to the effects of three structurally distinct Pin1 inhibitors (PiB 47 , EGCG 48 and Juglone 49 ) on NB4 human APL cells in vitro. These three inhibitors are less potent than ATRA and also have other targets and toxicities 27 . Similarly to ATRA, these agents dose-dependently reduced PML-RAR-α expression in NB4 human APL cells, but they inhibited Pin1 without degrading it (Fig. 4a) . However, in contrast to ATRA or the pan-RAR activator, neither these Pin1 inhibitors nor Pin1 shRNA induced NB4 human APL cell differentiation (Fig. 4b) . These results were further supported by the observation that ATRA but not Pin1 shRNA induced the expression of RAR target genes ( Supplementary Fig. 5i) ; the minimal effect of Pin1 shRNA could be attributed to the stabilization of the RAR protein mediated by Pin1 shRNA, as shown previously 45 .
To examine the effects of these Pin1 inhibitors on APL in vivo, we retro-orbitally injected sublethally irradiated B6 mice with APL cells isolated from CTSG-PML-RARA transgenic mice, which express human PML-RAR-α under the control of the myeloid/promyelocyticspecific cathepsin G gene promoter 50 npg marrow by flow cytometry. ATRA, but neither EGCG nor Juglone, induced APL cell differentiation (Fig. 4c) . Moreover, ATRA, but neither EGCG nor Juglone, reduced Pin1 levels in the bone marrow (Fig. 4d) , although the reduction was not as profound as observed in vitro (Fig. 4a) , probably because of the presence of normal cells in bone marrow, which were usually more resistant to ATRA (Figs. 2a  and 5a,b) . Nevertheless, all three Pin1 inhibitors effectively reduced PML-RAR-α protein expression in the bone marrow (Fig. 4d) and treated APL, with spleen weights nearly at basal levels ( Fig. 4e and Supplementary Fig. 8e ). Unlike ATRA-treated animals, EGCG-or Juglone-treated mice were rather sick, probably because of the fact that EGCG and Juglone have other toxic effects 27 . These results are consistent with the previous findings that ATRA's ability to activate RARs and induce leukemia cell differentiation can be uncoupled from its ability to degrade PML-RAR-α and treat APL 39, 40 .
Next we determined whether ATRA treatment degrades Pin1 and PML-RAR-α in APL cells in humans. We used double immunostaining with antibodies against Pin1 and PML to detect Pin1 and PML-RAR-α abundance and localization in cells from the bone marrow of healthy individuals, APL patients before or after ATRA treatment for 3 or 10 d, or individuals in complete APL remission (Supplementary Table 3) , as described 7, 51 . In contrast to healthy controls, Pin1 and PML-RAR-α were markedly overexpressed and distributed throughout the entire nuclei of cells from all subjects with APL who were examined before treatment (Fig. 4f-h) . After ATRA treatment, PML-RAR-α levels were markedly reduced, with fluorescence signal detected mainly in PML nuclear bodies (Fig. 4f) . Of note, reduced fluorescence signal, mainly in PML nuclear bodies, represents endogenous PML protein and reflects a good ATRA response 51 . Importantly, ATRA treatment caused a time-dependent reduction of Pin1 and PML-RAR-α expression to ~40% or <10% after 3 or 10 d of treatment, respectively (Fig. 4f-h) . Notably, PML-RAR-α/PML staining colocalized with Pin1 staining in APL cells. PML-RAR-α/PML was still diffusely distributed throughout the entire nuclei of APL cells containing more Pin1 (Fig. 4f) , but it was almost exclusively localized to PML bodies (probably reflecting endogenous PML) in APL cells npg that contained less Pin1 (Fig. 4f) . Similar results were also obtained by treating NB4 human APL cells with ATRA in vitro ( Supplementary  Fig. 9 ). Notably, neither Pin1 nor PML-RAR-α was overexpressed in individuals who were in complete APL remission (Fig. 4f-h) . Thus, Pin1 inhibition by ATRA, other chemical compounds or shRNA caused PML-RAR-α degradation in APL mouse models and human APL cells in vitro as well as in APL patients.
ATRA as a candidate breast cancer therapy Given that Pin1 regulates numerous cancer-driving molecules in solid tumors (Supplementary Fig. 1 ), we hypothesized that ATRA might have anticancer activity against other malignancies. We explored this in breast cancer because of the substantial oncogenic role of Pin1 in this disease 9, 10, 12 . We treated nine different human normal and breast cancer cell lines with ATRA and examined cell proliferation by the colorimetric MTT assay. Non-transformed MCF10A and HMLE cells were highly resistant to ATRA, and different malignant cells showed differential susceptibility to ATRA (Fig. 5a ).
Compared to MCF10A and HMLE cells, Pin1 was overexpressed in all breast cancer cells 11 (Fig. 5b) . These cells expressed similar levels of cytochrome P450-dependent retinoic acid-4-hydroxylase (Fig. 5b) , and treatment with its inhibitor, liarazole, resulted in generally additive effects with ATRA ( Supplementary Fig. 10c ), suggesting that differences in ATRA metabolism probably do not account for the observed difference in ATRA sensitivity. Because the Pin1-ATRA co-crystal structure revealed that the carboxyl group of ATRA formed salt bridges with K63 and R69 of Pin1 (Fig. 1i) Figs. 2a and 10a) , we examined the possibility that S71 phosphorylation affects ATRA sensitivity. Indeed, the levels of S71 phosphorylation in different cell lines were inversely correlated with ATRA sensitivity (Fig. 5b) . Given that S71 in Pin1 is phosphorylated by DAPK1 (ref. 7), a tumor suppressor whose expression is often lost in solid tumors 28 , we examined the expression of Pin1 and DAPK1 in human TNBC tissues (Supplementary Table 4) . High Pin1 but low DAPK1 expression was detected in most breast cancer tissues with an inverse correlation (n = 48) (Fig. 5c and Supplementary Fig. 10b) .
To examine whether the inhibitory effects of ATRA on breast cancer cell growth are related to RAR activation, we again used Ro-415253 and AC-93253. As in APL cells, neither compound had obvious effects on the ability of ATRA to induce Pin1 degradation or inhibit proliferation of breast cancer cells (Supplementary Fig. 10d-g ).
To further support the thesis that ATRA targets Pin1 in breast cancer, we next examined the effect of ATRA on the abundance of a set of oncogenes and tumor suppressors whose stability is regulated by Pin1 in breast cancer 2, 3 . Indeed, treatment with ATRA caused a dose-dependent decrease in the abundance of Pin1 and its substrate oncoproteins, including cyclin D1 (ref. (Fig. 5d) . ATRA had no appreciable effects on MCF10A cells (Fig. 5d) . To further support the notion that these effects are due to Pin1 ablation, we stably introduced Tet-on Pin1 shRNA into these cells. Inducible Pin1 KD had the effects on the proteins encoded by oncogenes and tumor suppressors that were similar to those of ATRA treatment (Fig. 5d,e) ; these effects were rescued by reconstitution of shRNA-resistant Pin1, but not its W34/K63A mutant (Fig. 5f) . Thus, ATRA selectively ablates active nonphosphorylated Pin1 and thereby inhibits multiple cancerdriving pathways in estrogen receptor (ER)-positive, HER2-positive, and triple-negative human breast cancer cells.
To determine whether ATRA inhibits breast tumor growth in vivo, we used the MDA-MB-231 and MDA-MB-468 human TNBC cell lines; we selected TNBC because it has the worst prognosis and the fewest treatment options. In pilot experiments, MDA-MB-231 cells were subcutaneously injected into the flanks of female nude mice, and beginning 1 week later mice were treated with either ATRA (33.0 µmol/kg) or vehicle intraperitoneally three times a week for 8 weeks. ATRA had only modest antitumor activity (Supplementary Fig. 10h) , which is consistent with the findings from clinical trials that ATRA has moderate efficacy against advanced breast cancer 35, 52 ; this could be due to its short half-life of ~45 min in humans 53 .
We thus implanted either ATRA-releasing or placebo pellets (to maintain a constant level of the drug) 1 week after injecting TNBC cell lines into the flanks of nude mice. We followed tumor growth for 8 weeks after implantation of ATRA pellets. ATRA pellets potently and dose-dependently inhibited tumor growth and reduced the abundance of Pin1 and its substrate cyclin D1 in tumors derived from both MDA-MB-231 (Fig. 6a,b) and MDA-MB-468 cells (Fig. 6c,d) , as compared to placebo pellets. Similar dose-dependent inhibition of tumor growth was also observed when ATRA was first administered 3 weeks after MDA-MB-231 tumor cell inoculation, when tumors were already formed (Fig. 6e) . To test whether the antitumor activity of ATRA against breast cancer was mediated by Pin1, we stably expressed Pin1 in MDA-MB-231 cells before injecting them into the flanks of nude mice. Pin1 overexpression markedly increased tumor growth (by approximately eightfold), which again was effectively inhibited by ATRA in a dose-dependent manner (Fig. 6f) . ATRA also dose-dependently reduced both endogenous and exogenous Pin1 and endogenous cyclin D1 (Fig. 6g) . Thus, ATRA has potent antitumor activity against TNBC through ablation of Pin1 and its multiple cancer-driving pathways at the same time.
DISCUSSION
The use of ATRA in APL therapy has been described as the first example of targeted therapy in human cancer [36] [37] [38] , but its drug target(s) remain elusive. Notably, retinoic acid-mediated transactivation is dispensable for leukemia initiated by PML-RAR-α (ref. 54 ). ATRA's ability to activate RARs and induce leukemia cell differentiation can be uncoupled from its ability to induce PML-RAR-α degradation, inhibit APL stem cells, and treat APL 39, 40 . ATRA's ability to activate RARs cannot explain its activity to regulate the protein stability of other oncogenic 41, 42 and tumor-suppressive 43 molecules. Finally, regular ATRA, even with a half-life of 45 min, has moderate but detectable efficacy against solid tumors in some clinical trials, and new generations of supposedly much more potent retinoid derivatives that target RARs or RXRs show little efficacy 35, 52, [55] [56] [57] .
Our mechanism-based screening has led to the unexpected discovery that ATRA directly binds, inhibits and ultimately degrades active Pin1 selectively. This selectivity was confirmed by solving the Pin1-ATRA co-crystal structure, which reveals that the carboxylic and aromatic moieties of ATRA occupy the Pin1 substrate phosphateand Pro-binding pockets in the Pin1 active site, respectively, and that S71 phosphorylation prevents ATRA from binding Pin1 by blocking the carboxyl-binding pocket. Notably, the ATRA carboxylic moiety mimics S71 phosphorylation by the tumor suppressor DAPK1, which inhibits Pin1 activity and oncogenic function 7 npg An ATRA-releasing formulation effectively treated in situ APL and TNBC mouse models, which reportedly produces a 0.6 µM drug plasma concentration 40 . ATRA effectively degraded Pin1 and PML-RAR-α in APL cells in human patients at standard doses, which reportedly produce a 1.2 µM drug plasma concentration 58 . Thus, Pin1 is a critical direct target of ATRA for inducing PML-RAR-α degradation and treating APL, and it is likely to be the long-sought-after drug target of ATRA in the treatment of APL (Supplementary Fig. 11a ). Of note, it has been reported that Pin1 inhibition enhances the responses of APL cells to ATRA via stabilization of PML-RAR-α (ref. 59) , which is consistent neither with the previous findings that PML-RAR-α causes APL and that ATRA induces PML-RAR-α degradation to treat APL 39,40 nor with our current findings that ATRA induces PML-RAR-α degradation by directly binding to and degrading Pin1. Moreover, that study did not suggest that ATRA directly targets Pin1 (ref. 59) .
Our findings offer a promising new approach for targeting a common oncogenic mechanism to stop numerous cancer-driving molecules and inhibit cancer stem cells at the same time ( Supplementary  Fig. 11a,b) , which is critically needed for treating aggressive or drugresistant cancers 1 . Although ATRA has only modest antitumor activity, ATRA-releasing pellets potently inhibit TNBC tumor growth by ablating Pin1 and its targets. Notably, liposomal ATRA, which has a longer half-life, has significant efficacy in APL patients even as a single-agent front-line therapy 60 . Consistent with this finding is that regular unmodified ATRA has moderate but detectable efficacy against advanced breast cancer in trials 35, 52 . It would be interesting to examine whether cells from those patients who do respond to ATRA treatment show Pin1 degradation, and whether outcomes improve if one could select those patients who respond to ATRA treatment. These results underscore the importance of developing ATRA that has a longer half-life, as doing so would improve its anticancer potency.
Our ATRA-Pin1 co-crystal structure provides insight that ATRA binds to Pin1 by taking advantage of the substrate phosphate-and proline-binding pockets in the Pin1 active site. However, unlike a substrate, the carboxylic and aromatic moieties in ATRA are linked by double bonds, which cannot be isomerized by Pin1. As a result, ATRA may be trapped in the Pin1 active site and inhibit its catalytic activity, ultimately leading to Pin1 degradation, which is supported by the requirement of ATRA binding for ATRA-induced Pin1 degradation. These results could help explain why ATRA seemed to be more potent in vivo than in enzyme-based assays in vitro. Furthermore, the ATRA-Pin1 structure helps explain why the new retinoid derivatives fenretinide and bexarotene 33, 34 exhibit much lower affinity for Pin1 than ATRA, which may contribute to their failure in the treatment of solid tumors 35, 56, 57 .
Our findings also provide a strong rationale for developing more potent and specific Pin1-targeted ATRA derivatives for cancer therapy. Comparisons of the Pin1 structures with ATRA and other potent in vitro Pin1 inhibitors 27 have identified additional modifications that can be introduced into ATRA to increase its affinity and specificity for Pin1 while reducing its affinity for RARs and possibly improving its half-life. Notably, it is unlikely that ATRA-like Pin1 inhibitors would have major general toxicity because of their selectivity for the active form of Pin1 that is overexpressed in many cancer cells, in addition to the fact that Pin1-KO mice have no obvious defects for an extended period of time 25, 26 . Indeed, ATRA 37, 38 and even liposomal ATRA 60 have not been reported to cause major toxicity.
In summary, we showed that ATRA directly binds, inhibits and ultimately degrades the active form of Pin1 that is overexpressed in many cancer cells to exert potent anticancer activity against APL and TNBC, probably by blocking multiple cancer-driving pathways at once. As regular ATRA has a short half-life of 45 min with moderate anticancer activity against solid tumors in humans, our results provide a rationale for developing either ATRA that has a longer half-life or more potent and specific Pin1-targeted ATRA derivatives for cancer treatment. sequentially. Antigen retrieval was performed by boiling samples in an autoclave device for 20 min in 1× antigen retrieval Citra (Biogene). Samples were blocked with PBS containing 5% goat serum and 0.1% Triton X-100, followed by incubation with anti-Pin1 antibody (against nonphosphorylated Pin1, 1:200) or anti-DAPK antibody (1:500) at 4 °C in a humidified chamber for 12 h. After extensive washes with PBS, samples were incubated with biotinylated secondary antibody for 2 h and visualized with the Vectastain ABC kit and DAB-staining solution (Vector Laboratories). In each sample, expression of Pin1 or DAPK1 was semi-quantified manually in a double-blind manner as high, medium or low according to the standards presented in Figure 6c . The correlation of Pin1 expression and DAPK1 expression in 48 human TNBC tissues was analyzed by Spearman's rank correlation test (P < 0.001).
METHODS

Methods
Genome-wide gene expression profiling. NB4 human APL cells were treated with 10 µM ATRA (Sigma-Aldrich) or doxycycline-induced Pin1 knockdown for 3 d, and total RNA was extracted with the Trizol reagent according to the manufacturer's instructions. The samples were then processed using Affymetrix GeneChip WT PLUS Reagent Kit, followed by Hybridization Wash and Stain Kit. Microarray expression profiles were collected using Affymetrix Human Transcriptome Array 2.0. Original CEL files were analyzed by the Affymetrix software programs Expression Console and Transcriptome Analysis Console. Microarray data have been deposited in NCBI Gene Expression Omnibus with series accession number GSE63059. Genes with lower expression in Pin1-KD or ARTA-treated cells than in vec or DMSO-treated cells with a fold change < 0.5 (P < 0.05) were selected as downregulated ones, and those with higher expression in Pin1 KD or ARTA-treated cells than in vec or DMSO-treated cells with a fold change > 2 (P < 0.05) were selected as upregulated ones.
Crystallization and complex structure determination for Pin1 PPIase domain with ATRA. Pin1 PPIase domain (residue 51-163) was cloned into a pET28a derivative vector with an N-terminal hexahistidine tag followed by recognition sequences by thrombin and PreScission 3C proteases and then followed by the recombinant gene. Mutations of K77Q, K82Q were created by QuikChange sitedirected mutagenesis (Agilent Technologies).
The PPIase K77/82Q was purified similarly to a previous published method 29 with minor modifications. Briefly, PPIase K77/82Q was overexpressed in E. coli BL21 (DE3) cells with 1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) induction at 16 °C overnight. Cell lysate was first purified using nickel affinity chromatography. The elution was a dialysis in a buffer of 20 mM HEPES, 100 mM NaCl, 8 mM β-Mercaptoethanol (pH 8), while protein was treated with PreScission Protease (GE) overnight at 4 °C. After His-tag removal, Pin1 PPIase K77/82Q was separated from untruncated protein by a second round of nickel affinity chromatography, and then purified by size exclusion chromatography columns Superdex 75 (GE Healthcare).
Purified PPIase K77/82Q was concentrated to 15 mg/ml. ATRA dissolved in DMSO at the concentration of 1mM and was mixed with protein solution and incubated on ice for 3 h before setting up trays. Incubated protein was co-crystalized by vapor diffusion using a hanging drop of 1 µl protein-ATRA plus 1 µl well solution. The complex formed crystals in solutions containing 0.2 M ammonium sulfate, 0.1 M HEPES (pH 7-8.5) and 0.9-1.4 M sodium citrate after micro-seeding using apo-PPIase domain crystals. The crystals were cryoprotected by the addition of 30% glycerol in mother liquor and vitrified in liquid nitrogen before data collection.
X-ray diffraction was collected from synchrotron radiation at beamlines 5.0.2 of the Advanced Light Source (Berkeley, California) with 3 × 3 CCD array detectors (ADSC Q315R). Data were processed and scaled using the HKL 2000 software suite 64 . Data collection statistics are summarized in Supplementary  Table 1 .
The structure of PPIase K77/82Q bound with ATRA was determined by molecular replacement with PPIase K77/82Q (PDB: 3IKG) as the search model using program Phaser from the CCP4 package suite 65 . The structure was refined with the Refmac5 program from CCP4 package and iterative model building in COOT 66, 67 . The final structure was evaluated by both PROCHECK 68 and MolProbity 69 . Refinement statistics are summarized in Supplementary Table 1 . The Pin1-ATRA structure was deposited into the Worldwide Protein Data Bank with the PDB code of 4TNS.
Animal studies. For xenograft experiments, 2 × 10 6 of MDA-MB-231 or MDA-MB-468 parent cells or MDA-MB-231 cells expressing Pin1 or control vectors were injected subcutaneously into flank of 8-week-old female BALB/c nude mice (Jackson Laboratories). One week later, tumor growth was just about notable by sight, and mice were randomly selected to receive ATRA or control treatment. For intraperitoneal injection, vehicle or 12.5 mg/kg ATRA was administered three times a week for 8 weeks. For implantation, placebo, 5 or 10 mg over 21 d of ATRA-releasing pellets (Innovative Research of America) were implanted subcutaneously in the back of nude mice. Tumor sizes were recorded weekly by a caliper for up to 8 weeks and tumor volumes were calculated using the formula: L × W 2 × 0.52, where L and W represent length and width, respectively. For NB4 cell transplantation, 8-week-old NOD.Cg-prkdc scid ll2rg tm1Wjl /SzJ (termed NSG) mice (Jackson Laboratory) 70 were used as recipients after sublethal irradiation at 350 Gy. Each mouse was transplanted with 5 × 10 5 NB4 cells stably expressing Tet-on shPin1 via retro-orbital injection. Five days later, when transplanted cells had established, mice were randomly selected to receive regular or doxycycline-containing food and survival curves were recorded. For PML-RAR-α transgenic cell transplantation, C57BL/6 mice were given 350 Gy irradiation followed by transplantation with 1 × 10 6 APL cells from CTSG-PML-RARA transgenic mice 50, 71 . After 5 d, when transplanted cells had established, mice were randomly selected to receive placebo (21 d placebo-releasing pellets, subcutaneously), ATRA (5 mg of 21d ATRA-releasing pellets, subcutaneously), EGCG (12.5 mg/kg/d, intraperitoneally), or Juglone (1 mg/kg/d, intravenously). Mice were sacrificed after 3 weeks, when APL blast cells appeared in a peripheral blood smear of placebo-treated mice. Spleen weight was measured and bone marrow was collected for immunoblotting of PML-RAR-α and Pin1 expression. No animals were excluded during the experiments. Animal work was carried out in compliance with the ethical regulations approved by the Animal Care Committee, Beth Israel Deaconess Medical Center, Boston, USA.
Human APL samples. Bone marrow aspirates were obtained with informed consent from the iliac crests of individuals in whom the diagnosis of acute promyelocytic leukemia was suspected based on a morphological evaluation of their peripheral blood smears. Immediately after the procedure, therapy with ATRA was started 72, 73 . Second bone marrow aspirate samples were obtained on day 3 or 10 of ATRA therapy. Samples tested positive for the PML-RAR-α rearrangement by RT-PCR. The human sample collection was approved by the Institutional Review Board at the University of São Paulo (HCRP no. 13496/2005) or at Tor Vergata University (IRB no. 12/07).
Statistical analysis.
Experiments were routinely repeated at least three times, and the repeat number was increased according to effect size or sample variation. We estimated the sample size considering the variation and mean of the samples. No statistical method was used to predetermine sample size. No animals or samples were excluded from any analysis. Animals were randomly assigned to groups for in vivo studies; no formal randomization method was applied when assigning animals for treatment. Group allocation and outcome assessment was not done in a blinded manner, including for animal studies. All data are presented as the means ± s.d., followed by determining significant differences using the two-tailed student's t-test or analysis of variance (ANOVA) test, where *P < 0.05, **P < 0.01, ***P < 0.001.
